Dr. Mark Agulnik, MD
Medical Oncology (Medical Oncology Physician)
1441 Eastlake Ave
Los Angeles, CA 90089
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 85
Licensed in Illinois since 2007, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license C170270 (first issued 2020; current) · IL license 036-118071 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Keck Hospital of Usc Los Angeles, CA
Medical groups
- Usc Care Medical Group Inc (1,380 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 85
- Services billed
- 226
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 315 | 131 |
| Established patient office or other outpatient visit, 30-39 minutes | 162 | 99 |
| New patient office or other outpatient visit, 60-74 minutes | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 55 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 54 payments worth $29,811 in total to this clinician.
| Deciphera Pharmaceuticals Inc. | $27,155 |
|---|---|
| Daiichi Sankyo Inc. | $2,099 |
| Springworks Therapeutics, Inc. | $139 |
| Tempus Ai, Inc | $78.99 |
| Bayer HealthCare Pharmaceuticals Inc. | $65.25 |
| Sobi, Inc | $61.69 |
| Genzyme Corporation | $57.93 |
| Beone Medicines USA, Inc. | $41.01 |
| Compensation for services other than consulting (speaking, faculty) | $24,638 |
|---|---|
| Consulting Fee | $2,025 |
| Travel and Lodging | $1,483 |
| Food and Beverage | $1,453 |
| Gift | $212 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $10,413 |
| Deciphera Pharmaceuticals Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $4,110 |
| Deciphera Pharmaceuticals Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,273 |
| Deciphera Pharmaceuticals Inc. Dec 30, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,273 |
| Deciphera Pharmaceuticals Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $2,380 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,025 |
| Deciphera Pharmaceuticals Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $595 |
| Deciphera Pharmaceuticals Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $595 |
| Deciphera Pharmaceuticals Inc. Apr 2, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL · in-kind | $497 |
| Deciphera Pharmaceuticals Inc. Apr 3, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL · in-kind | $467 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Dec 30, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,273 |
| Deciphera Pharmaceuticals Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $595 |
| Daiichi Sankyo Inc. Dec 3, 2025 | Consulting Fee Turalio · ONCOLOGY | $2,025 |
| Deciphera Pharmaceuticals Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $2,380 |
| Deciphera Pharmaceuticals Inc. Nov 25, 2025 | Travel and Lodging ROMVIMZA · ONCOLOGY · travel to BOCA RATON, FL | $376 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $87.29 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $63.36 |
| Deciphera Pharmaceuticals Inc. Nov 12, 2025 | Gift ROMVIMZA · ONCOLOGY · in-kind | $61.14 |
| Deciphera Pharmaceuticals Inc. Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,273 |
| Deciphera Pharmaceuticals Inc. Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $595 |
| Deciphera Pharmaceuticals Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $4,110 |
| Deciphera Pharmaceuticals Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $10,413 |
| Deciphera Pharmaceuticals Inc. Apr 18, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL | $97.99 |
| Deciphera Pharmaceuticals Inc. Apr 18, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL | $44.80 |
| Deciphera Pharmaceuticals Inc. Apr 3, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL · in-kind | $467 |
| Deciphera Pharmaceuticals Inc. Apr 2, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL · in-kind | $497 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $52,706 in research payments for these studies, mostly to the institutions running them.
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Epizyme, Inc. · Terminated · NCT04204941 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.